Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig.7.C
Gur M et al. (2022)
|
Xla Wt + aldh1a2 CRISPR
NF12 (RT-PCR)
|
|
|
|
Fig.3.A-G
Gur M et al. (2022)
|
Xla Wt + DEAB
NF10.25 (RT-PCR)
|
|
|
|
Fig.1.H
Gur M et al. (2022)
|
Xla Wt + DEAB
NF10.25 (RT-PCR)
|
|
|
|
Fig.3.A-G
Gur M et al. (2022)
|
Xla Wt + Retinoic acid
NF10.25 (RT-PCR)
|
|
|
|
Fig.7.C
Gur M et al. (2022)
|
Xla Wt + Retinoic acid
NF12 (RT-PCR)
|
|
|
|
Fig. 7 A row 1 col 1
Jalvy S et al. (2019)
|
Xla Wt + lif
NF 12.5 (RT-PCR)
|
|
|
|
Fig. 5 h i
Harata A et al. (2019)
|
Xla Wt + p2ry4
NF9 (in situ hybridization)
|
|
|
|
Fig. 4 l
Harata A et al. (2019)
|
Xla Wt + p2ry4 TALEN
NF11 (in situ hybridization)
|
|
|
|
fig.S8.b
Miyagi A et al. (2015)
|
Xla Wt + rhoa
NF9 (in situ hybridization)
|
|
|
|
fig.S8.b
Miyagi A et al. (2015)
|
Xla Wt + XB5959819 [provisional]
NF9 (in situ hybridization)
|
|
|